Concluding, we see many avenues of further study that are needed both in the pre-clinical and clinical space in order to further understand the role of CD73 and the adenosine pathway overall across not just lung cancer but, also other cancers with an activated adenosine pathway. The gene discussed is NT5E; the disease is lung carcinoma.